Contents

Treatment of age-related macular degeneration with photodynamic therapy (TAP)

October 1999

Clinical trial

Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials–TAP report.

Arch Ophthalmol. 1999 Oct;117(10):1329-45.
Full text

Main finding: Verteporfin therapy of subfoveal CNV from AMD can decrease the risk of vision loss and is recommended for predominantly classic CNV from AMD.

 

  • Purpose: To determine if photodynamic therapy with verteporfin can safely reduce the risk of vision loss in patients with subfoveal choroidal neovascularization caused by age-related macular degeneration.
  • Study type: Randomized clinical trial
  • Condition: CNV secondary to AMD

Participants: Subfoveal CNV, BCVA 20/40-20/200, with evidence of classic CNV pattern on FFA.

 

  • n=609

 

Intervention:

 

Group 1: Verteporfin PDT
Group 2: Placebo

Patients who received Verteporfin PDT had better visual acuity and contrast sensitivity outcomes at 12 months compared to placebo.

 

This benefit was especially seen in patients with predominantly classic (>50% of the lesion) CNV.

 

No statistically significant differences in visual acuity were noted in patients with classic CNV between 0-50% of the lesion area.

 

 

Verteporfin PDT Placebo
Lost at least 15 letters Total 61% 46%
Classic CNV > 50% of entire lesion 67% 39%

Share This Article :

Updated on March 7th, 2022

Source Archive

© 2024 - sourceshed